Pharvaris CCO files Form 3 equity holdings

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. Chief Commercial Officer Wim Souverijns filed a Form 3 reporting his initial equity holdings in the company. As of March 18, 2026, he holds 55,111 shares of common stock directly, including restricted stock units that settle in common shares.

He also reports multiple stock option awards on common stock, such as 55,000 underlying shares at an exercise price of 28.0000 per share expiring on March 3, 2036, and 75,000 underlying shares at 8.0500 per share expiring on April 6, 2033. Footnotes describe time-based vesting schedules, typically with 25% vesting on a specified date and the remainder vesting in equal monthly installments over 48 months.

Insider Trade Summary

7 transactions reported

Mixed 7 txns

Insider Souverijns Wim

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Stock Option (Right to Buy)	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 422,500 contracts (Direct); Common Stock — 55,111 shares (Direct)

Footnotes (7)

F1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -18,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -7,708 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.
F2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.
F3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.
F4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.
F5. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.
F6. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.
F7. 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Pharvaris (PHVS) Form 3 filing by Wim Souverijns report?

The Form 3 reports Chief Commercial Officer Wim Souverijns’ initial equity holdings in Pharvaris. It lists his common stock position and several stock option grants and restricted stock units with specified exercise prices, vesting schedules, and expiration dates as of March 18, 2026.

How many Pharvaris (PHVS) common shares does Wim Souverijns hold?

Wim Souverijns holds 55,111 Pharvaris common shares directly as of March 18, 2026. This figure includes restricted stock units that settle in common stock and are reported as non-derivative securities, subject to time-based vesting conditions described in the footnotes.

What stock option awards are reported for Wim Souverijns in Pharvaris (PHVS)?

The filing shows several stock option awards on Pharvaris common stock. Examples include 55,000 underlying shares at 28.0000 per share expiring March 3, 2036, and 75,000 underlying shares at 8.0500 per share expiring April 6, 2033, all held directly by Souverijns.

How do Wim Souverijns’ Pharvaris (PHVS) stock options vest?

Footnotes state each option grant vests 25% on a specified initial vesting date, with the remaining shares vesting in 1/48 monthly installments. For example, options expiring July 1, 2032 and April 6, 2033 each had 25% vest earlier, with the balance vesting monthly thereafter.

What restricted stock units (RSUs) are disclosed for Wim Souverijns at Pharvaris (PHVS)?

The filing notes RSUs from awards granted on March 3, 2026, March 12, 2025, and April 11, 2024. Each grant vests 25% on its one-year anniversary date, with remaining units vesting monthly. All RSUs settle in Pharvaris common stock and are included in his reported share holdings.

Does the Pharvaris (PHVS) Form 3 show any stock purchases or sales by Wim Souverijns?

The Form 3 functions as an initial ownership report and shows holdings only. The transaction summary indicates no buy, sell, exercise, gift, or tax-withholding transactions; it simply lists existing common stock, RSUs, and stock option positions as of March 18, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/18/2026 - 02:23 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Souverijns Wim

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	55,111⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾	03/03/2036	Common Stock	55,000	$28	D
Stock Option (Right to Buy)	⁽³⁾	04/12/2035	Common Stock	67,500	$16.05	D
Stock Option (Right to Buy)	⁽⁴⁾	04/11/2034	Common Stock	45,000	$22.31	D
Stock Option (Right to Buy)	⁽⁵⁾	04/06/2033	Common Stock	75,000	$8.05	D
Stock Option (Right to Buy)	⁽⁶⁾	04/01/2032	Common Stock	65,000	$18.14	D
Stock Option (Right to Buy)	⁽⁷⁾	07/01/2031	Common Stock	115,000	$17.43	D

Explanation of Responses:

1. Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -18,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -17,250 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -7,708 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter.

2. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter.

3. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter.

4. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter.

5. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

6. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter.

7. 25% of the option vested on July 1, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Wim Souverijns	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR